Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Advances in Targeted Therapies and ADCs in Gynecologic Cancer Are Highly Anticipated at the 2025 ESMO Congress

October 1st 2025

Experts in the gynecologic cancer landscape highlight their most anticipated presentations ahead of the 2025 ESMO Congress.

Dr Vose on Common Adverse Effects With Epcoritamab in Relapsed/Refractory LBCL

September 30th 2025

Julie M. Vose, MD, MBA, discusses the safety profile of epcoritamab in patients with relapsed/refractory LBCL who have achieved a 2-year complete response.

Dr Lee on Disease-Free Survival Outcomes With Alectinib in ALK+ NSCLC

September 30th 2025

Matthew Lee, MD, details the improved disease-free survival outcomes with adjuvant alectinib in patients with ALK-positive NSCLC.

CCR4-Directed Strategy Achieves Durable Response in T-Cell Lymphoma Following Treatment with Anti-BCMA CAR T-Cell Therapy

September 30th 2025

Samir Parekh, MD, discusses managing a rare T-cell lymphoma post BCMA CAR T-cell therapy and how CCR4-targeted treatment achieved durable remission.

Ropeginterferon Alfa-2b Generates Superior Efficacy vs Anagrelide in High-Risk Essential Thrombocythemia

September 30th 2025

Higher response rates were shown with second-line ropeginterferon alfa-2b compared with anagrelide in patients with high-risk essential thrombocythemia.

Real-World Evidence Complements and Contextualizes Randomized Clinical Trial Insights in Colorectal Cancer

September 30th 2025

While clinical trials are considered a “gold standard” in identifying the efficacy of treatments, real-world data help address unmet needs in colorectal cancer.

Dr Kuykendall on the Relevance of QOL End Points in Myelofibrosis Clinical Trials

September 29th 2025

Andrew Kuykendall, MD, discussed the advantages and limitations of using QOL- and symptom-related end points in myelofibrosis clinical research.

Dr Smith on the Use of Doublet vs Triplet Therapies in mHSPC

September 29th 2025

Matthew R. Smith, MD, PhD, discussed patient characteristics and disease factors that influence treatment intensification decisions in mHSPC.

Dr Khan on Key BTK Inhibitor Updates in Relapsed/Refractory CLL

September 26th 2025

Cyrus M. Khan, MD, discusses the key BTK inhibitor updates for the treatment of patients with relapsed/refractory CLL from the 2025 ASCO Annual Meeting.

Dr Strickler on the Rationale for Evaluating Temab-A in Chemo-Refractory Metastatic CRC

September 26th 2025

John H. Strickler, MD, details the impetus for evaluating the novel c-Met–directed ADC Temab-A in refractory metastatic colorectal cancer.

FDA Grants Utidelone Injection Orphan Drug Designation for Pancreatic Cancer

September 25th 2025

Utidelone injection has received orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.

Avantect Multi-Cancer and Ovarian Cancer Detection Tests Achieve UKCA Marking

September 25th 2025

A United Kingdom Conformity Assessed marking was granted to the Avantect Multi-Cancer Detection Test and Avantect Ovarian Cancer Test.

Zanubrutinib Shows Superior PFS vs Venetoclax/Obinutuzumab in Indirect Comparison of Treatment-Naive CLL

September 25th 2025

An indirect comparison of SEQUOIA and CLL14 shows zanubrutinib improved PFS over venetoclax/obinutuzumab in treatment-naive CLL after baseline adjustment.

Dr Rischin on the Efficacy of Adjuvant Cemiplimab in High-Risk CSCC

September 24th 2025

Danny Rischin, MD, discusses key DFS data from the phase 3 C-POST trial of adjuvant cemiplimab vs placebo in patients with high-risk CSCC.

Dostarlimab Plus Chemo Expands Frontline Options in Advanced/Recurrent Endometrial Cancer

September 24th 2025

Dana M. Chase, MD, discusses the effect of the frontline dostarlimab plus chemotherapy on the recurrent endometrial cancer landscape.

Radioligand Therapy Sequencing, Novel Targets Continue to Shape Prostate Cancer Care and Research

September 22nd 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the evolving role of radioligand therapies for the treatment of PSMA-positive prostate cancer.

Real-World Data Show Hematologic Responses With Pacritinib in Myelofibrosis With Anemia

September 22nd 2025

Treatment with pacritinib in a real-world clinical setting led to hemoglobin responses in 44% of patients with myelofibrosis and anemia.

Dr Tagawa on Factors for Lutetium Lu 177 Vipivotide Tetraxetan Use Before Docetaxel in mCRPC

September 18th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, details factors to consider when to use or defer docetaxel after lutetium Lu 177 vipivotide tetraxetan in mCRPC.

Dr Lorusso on the Rationale for Investigating Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

September 18th 2025

Domenica Lorusso, MD, PhD, details the rationale for the ROSELLA trial, evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Dr Ghia on Safety Considerations After Fixed-Duration Ibrutinib Plus Venetoclax in CLL

September 18th 2025

Paolo Ghia, MD, PhD, discusses the safety considerations of fixed-duration ibrutinib plus venetoclax after retreatment in patients with CLL.